Overview

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

Status:
Completed

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate treatment retention in psoriatic arthritis participants with STELARA or tumor necrosis factor alpha inhibitor (TNFi) therapies in relation to effectiveness, safety, benefit/risk and to examine clinical response.

Details

Lead Sponsor:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Antirheumatic Agents
Ustekinumab